Cancer clinical trials in the region Pays de la Loire

440 currently recruiting clinical trials
Region Pays de la Loire

Phase 3 Lung cancer #NCT05692999 #2023-503481-23-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
28 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3 Lung cancer #NCT05211895 #2023-506891-28-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy Radiotherapy
Excluded genetic anomalies
ALK EGFR
11 recruiting sites
AstraZeneca
Phase 3 Prostate cancer #NCT05116475 #2024-517285-41-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Hormone-sensitive
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 3 Prostate cancer #NCT06276465 #2023-507482-26-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Radiotherapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
10 recruiting sites
UNICANCER
Phase 3 Colon cancer Rectal cancer #NCT05253651 #2024-514180-25-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
KRAS G12C KRAS non G12C NRAS
18 recruiting sites
Seagen
Phase 3 Lung cancer #NCT05111197
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Institut de Cancérologie de l'Ouest
Phase 3 Breast cancer #NCT05078047
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Locally Advanced Metastatic
Required previous treatments at advanced or metastatic stage
Immunotherapy
24 recruiting sites
UNICANCER
Phase 3 Prostate cancer #NCT06496581
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Hormone-sensitive
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Internal Vectorised Radiotherapy (IVR)
10 recruiting sites
UNICANCER
Phase 3 Colon cancer Rectal cancer #NCT05078047
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MSI/dMMR
Required previous treatments at advanced or metastatic stage
Immunotherapy
24 recruiting sites
UNICANCER
Phase 3 Breast cancer #NCT06312176
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy
8 recruiting sites
Merck Sharp & Dohme LLC